Idenix Not Worth The Wait

HCV is a highly lucrative space to be in right now- witness the huge spike in Pharmasset’s share price merely on the presentation of tantalizing Phase 1 data. An entirely new class of treatments are emerging, reshaping the HCV landscape and creating multi-billion dollar opportunities. The rush is on to create a better- no, the […]

Pozen Gets Social To Sell Drugs

Pozen is a small, unconventional drug developer with two approved drugs and another expected to soon follow. The company specializes in devising novel formulations of existing drugs, allowing for an easier path to regulatory approval and lower cost of development. Its migraine drug, Treximet, is a combination of sumatriptan (Imitrex) and naproxen, and arthritis drug […]

Why is Exelixis Shrinking?

Exelixis has skyrocked over 300% from its August lows to its current price of about $12 on positive news for its lead compound, cabozantinib in prostate cancer, giving it a market cap of about $1.3 billioin. It is now positioned to file an NDA for its initial indication of medullary thyroid cancer (MTC) in the […]

Calistoga and Plexxikon: Gone in The Blink Of An Eye

I discussed the merits of these company’s in a short post back in June last year (Calistoga Pharmaceuticals and Plexxikon- Two Biotechs to Keep an Eye On). I had hoped to see them become public companies because I saw promise in their technologies and wanted to participate in their upside. Too late. Both have recently […]

Bionovo Completes Financing, Announces Plan of Action: Is the Worst Over?

Earlier this month, Bionovo (NASDAQ:BNVI), a development-stage pharmaceutical company, announced a plan of action for its lead product candidate, Menerba, an oral, botanical, drug candidate for the treatment of menopausal hot flashes. In the press release, the company clearly communicated its goal with regards to Menerba’s development timeline (click to enlarge images): This new timeline is […]

FDA Setbacks Make Vivus a Buying Opportunity

Vivus (NASDAQ:VVUS), a specialty pharmaceutical company, has faced some setbacks with its drug candidate, Qnexa, an investigational treatment for obesity, obstructive sleep apnea and diabetes. In October 2010, Vivus received a Complete Response Letter from the FDA, outlining a path to approval, which left investors who expected approval dissappointed. In January 2011, the company met […]

Depomed: Attractive and Under-Appreciated Potential

It almost seems counterintuitive that majority shareholders of Depomed (DEPO) have been adding shares after the FDA approval of Gralise, a once-daily treatment for post-herpetic neuralgia. One might expect that large funds would look to the high volume created with an FDA decision as an opportune exit strategy. Yet that hasn’t happened, several funds have […]

Genzyme Sold, Who’s Next?

Now that Genzyme has been acquired by Sanofi-Aventis, money managers have begun asking- where did all that money go? A Dow Jones Newswire article by Steven Russolillo reasoned that arbitrage players who held much of Genzyme shares have been quickly dividing that money between big and small name players for months now. Still, $20 billion […]

Eli Lilly: Plenty Of Talk, Now Time For Results

Eli Lilly CEO, John Lechleiter, Ph.D., has been making the rounds lately promoting innovation in pharmaceutical research. Most recently, he delivered the keynote speech at The Economist’s 2011 Pharma Summit: Reinventing Pharma for a New Generation this past February 10, in London. In his remarks, Lechleiter highlighted some of the problems facing the innovative drug […]

Alexion Goes From Acquisition Target To Acquirer

Alexion Pharmaceuticals reported revenues and major developments in its 2010 4th quarter report yesterday. Revenue continued climbing at a rapid clip, 2010 net product sales increased 40 percent to $541.0 million, compared to $386.8 million in 2009 and is projected to grow to between $715-$735 million in 2011. 2010 non-GAAP net income increased 54 percent […]

Idenix: Two Steps Forward and One Step Back

It has happened before- just when things were beginning to look up, Idenix has taken another beating. This time, the experimental AIDS drug it had licensed to ViiV Healthcare, an affiliate of GSK, had been placed on clinical hold by the FDA. The compound, IDX899, a non-nucleoside reverse-transcriptase inhibitor (NNRTI) had only begun Phase IIb […]

Ziopharm and Intrexon: Odd Couples

In January, Ziopharm announced a strategic deal with billionaire RJ Kirk’s synthetic biology company, Intrexon. In return for an $11,628,202 million investment in Ziopharm stock, Intrexon was issued 7.5% of Ziopharm stock and will receive an additional 7.5% once their lead candidate DC-IL-12 begins Phase II trials. From time to time, Kirk will also participate […]

Celgene: Is It Time To Buy?

Celgene has been hit again with issues of secondary malignancies arising from prolonged treatment with its key drug, Revlimid. Shares have crumbled in the past month from $60/sh early this year to as low as $49 on February 4. It has now bounced back above $50. News of secondary malignancies has bedeviled the company since […]

Of Billionaires and Biotechs

The biotech industry does not crank out billionaires. The long timelines to an improbable success combined with inevitable dilution of the founder’s stake makes it all but impossible. Consider that the collective market cap of all biotech companies is only about $360 billion, compared to about $320 billion for Apple alone. But a few men […]

Sales Potential and Chances of FDA Approval for DepoMed’s DM-1796

Many biotech investors have been closely watching the upcoming PDUFA date for DM-1796, DepoMed’s (DEPO) investigational extended-release gabapentin formulation. Depomed’s story has been marred with ups and downs, panicking those investors with a faint heart and forcing weak hands to exit, while the major funds continue to accumulate shares. To understand DM-1796’s approvability and its […]